Last reviewed · How we verify
Acetazolamide first, then Furosemide
Acetazolamide inhibits carbonic anhydrase, reducing the formation of bicarbonate ions and increasing urinary excretion of sodium, potassium, and water.
Acetazolamide inhibits carbonic anhydrase, reducing the formation of bicarbonate ions and increasing urinary excretion of sodium, potassium, and water. Used for Glaucoma, Edema, Seizures.
At a glance
| Generic name | Acetazolamide first, then Furosemide |
|---|---|
| Sponsor | Rabin Medical Center |
| Drug class | Carbonic anhydrase inhibitor |
| Target | Carbonic anhydrase |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 1 |
Mechanism of action
By inhibiting carbonic anhydrase, acetazolamide decreases the reabsorption of bicarbonate in the renal tubules, leading to increased excretion of bicarbonate, sodium, and water, which can help reduce intraocular pressure and treat glaucoma or edema.
Approved indications
- Glaucoma
- Edema
- Seizures
Common side effects
- Numbness and tingling
- Nausea
- Drowsiness
Key clinical trials
- Investigating a Tailored Diuretic Algorithm in Acute Heart Failure Patients (NA)
- Acetazolamide Versus Dapagliflozin in Acute Decompensated Heart Failure Patients (PHASE3)
- Effect of Acetazolamide and Furosemide on Obesity-induced Glomerular Hyperfiltration (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Acetazolamide first, then Furosemide CI brief — competitive landscape report
- Acetazolamide first, then Furosemide updates RSS · CI watch RSS
- Rabin Medical Center portfolio CI